BRPI0518315A2 - compostos de tiazol que modulam a atividade da proteÍna hsp90, mÉtodos de inibiÇço, tratamento e induÇço associados e composiÇço farmacÊutica - Google Patents

compostos de tiazol que modulam a atividade da proteÍna hsp90, mÉtodos de inibiÇço, tratamento e induÇço associados e composiÇço farmacÊutica

Info

Publication number
BRPI0518315A2
BRPI0518315A2 BRPI0518315-4A BRPI0518315A BRPI0518315A2 BR PI0518315 A2 BRPI0518315 A2 BR PI0518315A2 BR PI0518315 A BRPI0518315 A BR PI0518315A BR PI0518315 A2 BRPI0518315 A2 BR PI0518315A2
Authority
BR
Brazil
Prior art keywords
protein activity
treatment
pharmaceutical composition
methods
thiazole compounds
Prior art date
Application number
BRPI0518315-4A
Other languages
English (en)
Inventor
Weiwen Ying
David James
Shijie Zhang
Teresa Przewloka
Junghyun Chae
Dinesh U Manamada
Chi-Wan Lee
Elena Kostik
P Ng Howard
Kevin Foley
Zhenjian Du
James Barsoum
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35966006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0518315(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Publication of BRPI0518315A2 publication Critical patent/BRPI0518315A2/pt
Publication of BRPI0518315B1 publication Critical patent/BRPI0518315B1/pt
Publication of BRPI0518315B8 publication Critical patent/BRPI0518315B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTOS DE TIAZOL QUE MODULAM A ATIVIDADE DA PROTEÍNA Hsp9O, MÉTODOS DE INIBIÇAO, TRATAMENTO E INDUÇçO ASSOCIADOS E COMPOSIÇçO FARMACÊUTICA. A presente invençâo se refere a compostos de triazol substituidos e a composições que compreendem os compostos de triazol substituidos. A invençâo se refere ainda a métodos de inibiçào da atividade da proteína Hsp9O em um indivíduo com necessidade disso e a métodos para prevençào ou tratamento de distúrbios hiper-proliferativos, como o câncer, em um indivíduo com necessidade disso, compreendendo a administração a um indivíduo de um composto de triazol da invençâo ou uma composiçâo compreendendo tal composto.
BRPI0518315A 2004-11-18 2005-11-17 compostos de tiazol que modulam a atividade da proteína hsp90, métodos de inibição, tratamento e indução associados e composição farmacêutica BRPI0518315B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62897904P 2004-11-18 2004-11-18
US60/628,979 2004-11-18
US70935805P 2005-08-18 2005-08-18
US60/709,358 2005-08-18
US72504405P 2005-10-06 2005-10-06
US60/725,044 2005-10-06
PCT/US2005/041779 WO2006055760A1 (en) 2004-11-18 2005-11-17 Triazole compounds that modulate hsp90 activity

Publications (3)

Publication Number Publication Date
BRPI0518315A2 true BRPI0518315A2 (pt) 2008-11-11
BRPI0518315B1 BRPI0518315B1 (pt) 2020-11-17
BRPI0518315B8 BRPI0518315B8 (pt) 2021-05-25

Family

ID=35966006

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518315A BRPI0518315B8 (pt) 2004-11-18 2005-11-17 compostos de tiazol que modulam a atividade da proteína hsp90, métodos de inibição, tratamento e indução associados e composição farmacêutica

Country Status (21)

Country Link
US (4) US7825148B2 (pt)
EP (3) EP2295416B1 (pt)
JP (1) JP4954083B2 (pt)
KR (2) KR20140006070A (pt)
CN (2) CN103554042B (pt)
AU (1) AU2005306484C1 (pt)
BR (1) BRPI0518315B8 (pt)
CA (1) CA2586612C (pt)
DK (1) DK1817295T3 (pt)
ES (2) ES2594874T3 (pt)
HK (1) HK1107700A1 (pt)
HR (1) HRP20130095T1 (pt)
IL (1) IL183108A (pt)
ME (1) ME01498B (pt)
MX (1) MX2007005940A (pt)
NZ (1) NZ555158A (pt)
PL (1) PL1817295T3 (pt)
PT (1) PT1817295E (pt)
RS (1) RS52642B (pt)
TW (1) TWI380983B (pt)
WO (1) WO2006055760A1 (pt)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063222A1 (ja) * 2003-12-26 2005-07-14 Kyowa Hakko Kogyo Co., Ltd. Hsp90ファミリー蛋白質阻害剤
ES2594874T3 (es) * 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
EP1857446B1 (en) * 2005-03-09 2013-05-01 Nippon Kayaku Kabushiki Kaisha Derivatives of 3-(2,4-dihydroxyphenyl)-1,2,4-triazole useful in the treatment of cancer
ME01541B (me) 2005-04-13 2014-04-20 Astex Therapeutics Ltd DERIVATI HIDROKSIBENZAMIDA l NJIHOVA PRIMJENA KAO INHIBITORA HSP90
WO2007021966A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
CA2618724A1 (en) 2005-08-18 2007-02-22 Synta Pharmaceuticals Corp. Imidazole compounds that modulate hsp90 activity
JP5118039B2 (ja) 2005-08-18 2013-01-16 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
KR20080106254A (ko) 2006-03-28 2008-12-04 니폰 가야꾸 가부시끼가이샤 탁산류의 고분자 결합체
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
WO2007135910A1 (ja) 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha ポドフィロトキシン類の高分子結合体
WO2007139967A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
CA2653332A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2034996A2 (en) * 2006-05-25 2009-03-18 Synta Pharmaceuticals Corporation Triazole compounds that modulate hsp90 activity
AU2007267852A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate Hsp90 activity and methods for identifying same
US8063083B2 (en) 2006-05-25 2011-11-22 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
US20080125587A1 (en) * 2006-05-25 2008-05-29 Chimmanamada Dinesh U Synthesis of triazole compounds that modulate HSP90 activity
AU2012200157B2 (en) * 2006-05-25 2014-08-21 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
CA2659425C (en) * 2006-08-17 2017-06-20 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2664852A1 (en) 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of resorcinol derivatives
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008051416A2 (en) * 2006-10-19 2008-05-02 Synta Pharmaceuticals Corp. Compounds that inhibit the activity of hsp90 for treating infections
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
US20100280032A1 (en) * 2006-10-26 2010-11-04 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
EP2090607B1 (en) 2006-11-08 2015-05-20 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
MX2009008547A (es) 2007-02-08 2010-01-15 Synta Pharmaceuticals Corp Compuestos de triazol que son utiles en el tratamiento de trastornos proliferativos tales como cancer.
TW200904417A (en) * 2007-02-20 2009-02-01 Synta Pharmaceuticals Corp Triazole compounds that modulate Hsp90 activity
WO2008112199A1 (en) * 2007-03-12 2008-09-18 Synta Pharmaceuticals Corp. Method for inhibiting topoisomerase ii
US8648104B2 (en) 2007-05-25 2014-02-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with mutations in c-Met
JP5596543B2 (ja) * 2007-08-13 2014-09-24 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
WO2009041570A1 (ja) 2007-09-28 2009-04-02 Nippon Kayaku Kabushiki Kaisha ステロイド類の高分子結合体
JP4792128B2 (ja) * 2007-10-12 2011-10-12 アークル インコーポレイテッド 癌に対するｈｓｐ９０阻害剤としての５−（２−ヒドロキシフェニル）テトラゾール
GB0722680D0 (en) * 2007-11-19 2007-12-27 Topotarget As Therapeutic compounds and their use
KR100947696B1 (ko) * 2007-11-23 2010-03-16 재단법인서울대학교산학협력재단 1,2,4-트리아졸 유도체를 함유하는 Ｈｓｐ９０ 억제제 및이를 이용한 항암제
WO2009100130A1 (en) 2008-02-04 2009-08-13 Mercury Therapeutics, Inc. Ampk modulators
FR2928645A1 (fr) 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
US8920788B2 (en) 2008-03-18 2014-12-30 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of physiologically active substances
EP2284209B1 (en) 2008-05-08 2016-08-31 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
US9156836B2 (en) * 2008-05-16 2015-10-13 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate HSP90 activity
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
US8648071B2 (en) 2008-06-27 2014-02-11 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate Hsp90 activity
EP2323737A2 (en) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
ES2415234T3 (es) * 2008-08-08 2013-07-24 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad Hsp90
CN102421827B (zh) 2009-05-15 2014-07-30 日本化药株式会社 具有羟基的生理活性物质的高分子结合体
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
EA022119B1 (ru) 2009-10-19 2015-11-30 Синта Фармасьютиклз Корп. Комбинированная терапия раковых заболеваний с помощью соединений - ингибиторов hsp90
WO2011133520A1 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
EP2560641A2 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
US20130172333A1 (en) 2010-05-20 2013-07-04 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
WO2011146803A1 (en) 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
EP2575810A1 (en) 2010-05-24 2013-04-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
CA2809388A1 (en) 2010-08-23 2012-03-01 Daiichi Sankyo Company, Limited Crystal of a free tricyclic pyrazolopyrimidine derivative
AU2011302344B2 (en) 2010-09-13 2015-01-15 Synta Pharmaceuticals Corp. HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
KR20140024833A (ko) 2010-11-17 2014-03-03 니폰 가야꾸 가부시끼가이샤 신규한 시티딘계 대사길항제의 고분자 유도체
JP2014503500A (ja) 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
US20120128665A1 (en) 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment based on hypoxic status
US20140005145A1 (en) * 2010-12-08 2014-01-02 Synta Pharmaceuticals Corp. Combination breast cancer therapy with hsp90 inhibitory compounds
HUE025697T2 (en) 2010-12-20 2016-04-28 Sigma-Tau Res Switzerland S A Aryl triazole compounds having antitumor activity
US20130331357A1 (en) * 2011-01-11 2013-12-12 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
EP2678013A1 (en) * 2011-02-23 2014-01-01 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
CN103391779A (zh) * 2011-02-24 2013-11-13 辛塔医药品有限公司 使用hsp90抑制性化合物的前列腺癌治疗
US20140045908A1 (en) 2011-02-25 2014-02-13 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
US20140228418A1 (en) * 2011-05-23 2014-08-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
EP2714038A1 (en) 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
WO2012162584A1 (en) * 2011-05-26 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
JP2014520808A (ja) 2011-07-07 2014-08-25 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０阻害化合物を用いた癌の治療
AU2012299177A1 (en) * 2011-08-19 2014-04-10 Synta Pharmaceuticals Corp. Combination cancer therapy of HSP90 inhibitor with antimetabolite
RU2623426C2 (ru) 2011-09-11 2017-06-26 Ниппон Каяку Кабусики Кайся Способ получения блок-сополимера
AU2012332421A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Cancer therapy using a combination of Hsp90 inhibitors with topoisomerase I inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
JP2015515469A (ja) * 2012-03-28 2015-05-28 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０阻害剤としてのトリアゾール誘導体
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2013170159A1 (en) 2012-05-10 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
EP2887804B1 (en) 2012-05-22 2021-01-27 Trustees of Dartmouth College Cycloalkanyl[b]indoles useful as glp-1 modulators
AU2013331070A1 (en) * 2012-10-19 2015-05-07 Synta Pharmaceuticals Corp. Treating polycystic kidney disease with HSP90 inhibitory compounds
WO2015038649A1 (en) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015066053A2 (en) * 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015134464A2 (en) 2014-03-03 2015-09-11 Synta Pharmaceuticals Corp. Targeted therapeutics
KR101711732B1 (ko) * 2014-04-30 2017-03-02 경북대학교 산학협력단 3-아릴-1,2,4-트라이아졸 유도체 및 이의 용도
WO2015167211A1 (ko) * 2014-04-30 2015-11-05 경북대학교 산학협력단 3-아릴-1,2,4-트라이아졸 유도체 및 이의 용도
DK3179991T3 (da) 2014-08-11 2021-12-06 Acerta Pharma Bv Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
HUE059131T2 (hu) 2014-08-11 2022-10-28 Acerta Pharma Bv BTK-inhibitor, PD-1-inhibitor és/vagy PD-L1-inhibitor terápiás kombinációja
EP3248968A4 (en) * 2015-01-22 2018-11-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Resorcinol derivative as hsp90 inhibitor
AU2016219497A1 (en) 2015-02-09 2017-08-31 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors and PD-1 inhibitors for treating cancer
US9573936B2 (en) 2015-05-20 2017-02-21 Amgen Inc. Triazole agonists of the APJ receptor
CN106349233B (zh) * 2015-07-15 2021-06-01 上海翰森生物医药科技有限公司 3,4-二苯基-4h-1,2,4-三唑衍生物及其制备方法和应用
WO2017091513A1 (en) * 2015-11-24 2017-06-01 Daiichi Sankyo Company, Limited Novel azole derivatives as apelin receptor agonist
WO2017151554A1 (en) 2016-02-29 2017-09-08 Synta Pharmaceuticals Corp Combination therapy for treatment of ovarian cancer
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
EP3541804A1 (en) 2016-11-16 2019-09-25 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
CN111875583B (zh) * 2017-10-17 2021-06-15 中国科学院上海药物研究所 三氮唑衍生物及其制备方法和用途
EP3704122B1 (en) 2017-11-03 2021-09-01 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
EP3653611A1 (en) * 2018-11-15 2020-05-20 Centre National De La Recherche Scientifique Inhibitors of metallo-beta-lactamases
WO2020132384A1 (en) 2018-12-21 2020-06-25 Celgene Corporation Thienopyridine inhibitors of ripk2
TW202102268A (zh) * 2019-04-03 2021-01-16 美商塔維達治療公司 Ｈｓｐ９０靶定性共軛體類及其調製劑

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB928919A (en) * 1960-08-16 1963-06-19 Bellon Labor Sa Roger Triazole derivatives and a process for their preparation
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4178253A (en) * 1977-04-05 1979-12-11 Ciba-Geigy Corporation Corrosion inhibited lubricant compositions
US4269846A (en) * 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
JPS5770820A (en) 1980-10-20 1982-05-01 Haruo Ogura Immunoregulating agent
JPS5910574A (ja) 1982-07-07 1984-01-20 Fujisawa Pharmaceut Co Ltd トリアゾ−ル誘導体およびその製造法
FR2546887B1 (fr) 1983-05-30 1985-08-30 Paris 7 Universite Procede de preparation de dihydro-2,4 triazol-1,2,4 thiones-3 disubstituees en positions 4 et 5 et nouveaux composes pouvant etre prepares par ce procede
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4624995A (en) * 1985-04-09 1986-11-25 Minnesota Mining And Manufacturing Company Triazolinethione-containing polymer
US4740568A (en) * 1985-04-09 1988-04-26 Minnesota Mining And Manufacturing Company Triazolinethione-containing polymer
US5436252A (en) * 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
US5006650A (en) * 1987-02-11 1991-04-09 The Upjohn Company Novel N-1 substituted beta-lactams as antibiotics
DE3729070A1 (de) * 1987-09-01 1989-03-09 Bayer Ag Substituierte triazolinone
US5241074A (en) * 1988-05-09 1993-08-31 Bayer Aktiengesellschaft Sulphonylaminocarbonyltriazolinones
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5219722A (en) * 1990-09-21 1993-06-15 Konica Corporation Silver halide color photographic light-sensitive material
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
CA2129146A1 (en) * 1992-03-13 1993-09-16 Victor Giulio Matassa Imidazole, triazole and tetrazole derivatives
TW218017B (pt) * 1992-04-28 1993-12-21 Takeda Pharm Industry Co Ltd
DE4222771A1 (de) * 1992-07-10 1994-01-13 Bayer Ag Heterocyclyltriazolinone
DE4234801A1 (de) * 1992-10-15 1994-04-21 Bayer Ag Sulfonylaminocarbonyltriazolinone
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE4303376A1 (de) * 1993-02-05 1994-08-11 Bayer Ag Substituierte Triazolinone
DE4303676A1 (de) * 1993-02-09 1994-08-11 Bayer Ag 1-Aryltriazolin(thi)one
DE4411913A1 (de) * 1994-04-07 1995-10-12 Bayer Ag Substituierte Sulfonylaminocarbonyltriazolinone
US5538988A (en) * 1994-04-26 1996-07-23 Martinez; Gregory R. Benzocycloalkylazolethione derivatives
US5489598A (en) * 1994-06-08 1996-02-06 Warner-Lambert Company Cytoprotection utilizing aryltriazol-3-thiones
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JP3372365B2 (ja) * 1994-08-19 2003-02-04 富士写真フイルム株式会社 ハロゲン化銀写真感光材料およびそれを用いた画像形成方法
DE19502579A1 (de) * 1995-01-27 1996-08-01 Bayer Ag Sulfonylamino(thio)carbonyl-triazolin(thi)one
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
DE19521162A1 (de) * 1995-06-09 1996-12-12 Bayer Ag N-Aryl-1,2,4-triazolin-5-one
DE19525162A1 (de) * 1995-07-11 1997-01-16 Bayer Ag Sulfonylamino(thio)carbonylverbindungen
EP0839144B1 (en) 1995-07-13 2001-09-19 Knoll GmbH Piperazine derivatives as therapeutic agents
DE19540737A1 (de) * 1995-11-02 1997-05-07 Bayer Ag Substituierte Sulfonylamino(thio)carbonylverbindungen
DE19609059A1 (de) * 1996-03-08 1997-09-11 Bayer Ag Substituierte Arylsulfonylamino(thio)carbonyl-triazolin(thi)one
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
ZA974703B (en) * 1996-05-30 1997-12-30 Bayer Ag Substituted sulfonylamino(thio)carbonyl compounds.
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
DE19632945A1 (de) * 1996-08-16 1998-02-19 Bayer Ag Substituierte Sulfonylamino(thio)carbonylverbindungen
CA2269617A1 (en) * 1996-11-12 1998-05-22 Chris H. Senanayake 2r,4s,r,s- and 2s,4r,r,s-hydroxyitraconazole- and hydroxysaperconazole derivatives
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
JP3788676B2 (ja) * 1997-11-11 2006-06-21 富士写真フイルム株式会社 有機エレクトロルミネツセンス素子材料およびそれを使用した有機エレクトロルミネツセンス素子
EP1062208A1 (de) * 1998-03-09 2000-12-27 Basf Aktiengesellschaft Hetarylsubstituierte benzylphenylether, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen und tierischen schädlingen
US6185567B1 (en) * 1998-05-29 2001-02-06 The Trustees Of The University Of Pennsylvania Authenticated access to internet based research and data services
IT1302034B1 (it) * 1998-08-31 2000-07-20 Enirisorse Spa Catalizzatori superacidi solidi per l'isomerizzazione di idrocarburi eprocedimento sol-gel per il loro ottenimento
JP2000100570A (ja) 1998-09-25 2000-04-07 Toray Ind Inc 発光素子
JP2000284412A (ja) 1999-03-30 2000-10-13 Fuji Photo Film Co Ltd 熱現像写真材料
US6492406B1 (en) * 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US20040110684A1 (en) * 1999-08-02 2004-06-10 Universite Catholique De Louvain Novel pharmaceutical compositions for modulating angiogenesis
AU2001247759A1 (en) * 2000-03-24 2001-10-08 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US20030216385A1 (en) * 2000-05-19 2003-11-20 Takahiko Tobe Triazole derivatives
BR0110961A (pt) * 2000-05-19 2004-06-29 Merck Patent Gmbh Derivados de triazol
AU2001271567A1 (en) * 2000-06-29 2002-01-14 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
KR20030046397A (ko) * 2000-07-28 2003-06-12 슬로안-케테링인스티튜트퍼캔서리서치 세포증식성 질환 및 바이러스 감염의 치료 방법
JP2004512381A (ja) 2000-11-02 2004-04-22 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０インヒビターの使用により細胞毒性剤の効力を増強させる方法
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
AU2002252179A1 (en) 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
WO2002094259A1 (en) * 2001-05-03 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
WO2002094196A2 (en) * 2001-05-23 2002-11-28 Sloan Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated
JP4102124B2 (ja) 2001-08-01 2008-06-18 富士フイルム株式会社 ハロゲン化銀乳剤およびハロゲン化銀写真感光材料
EP1420747A4 (en) 2001-08-06 2010-06-02 Kosan Biosciences Inc ANSAMYCIN BENZOQUINONE
US20050154039A1 (en) 2001-11-28 2005-07-14 Marie-Odile Glacera Contour 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
US20050074457A1 (en) 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
DE60222804T2 (de) * 2001-12-21 2008-07-03 Vernalis (Cambridge) Ltd., Abington 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
EP1485088B1 (en) 2002-02-07 2008-08-06 The Curators Of The University Of Missouri Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
GB0207362D0 (en) 2002-03-28 2002-05-08 Univ Liverpool Chemotherapy
GB0208516D0 (en) 2002-04-15 2002-05-22 Univ Liverpool Chemotherapy
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
NZ541479A (en) 2003-02-11 2008-11-28 Vernalis Cambridge Liimited Isoxazole compounds as inhibitors of heat shock proteins
EP1457499A1 (en) 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
EP1605931A4 (en) 2003-03-13 2009-04-29 Conforma Therapeutics Corp MEDICINAL FORMULATIONS WITH LONG AND MEDIUM-CHAINED TRIGLYCERIDES
ATE479515T1 (de) 2003-03-17 2010-09-15 Seco Tools Ab Schneideinsatz mit ecken mit unterschiedlichen radien
BR0301799A (pt) 2003-04-09 2005-03-22 Elzo Ferreira Uso do processo de extração do extrato, da seiva, da tintura, da massa e dos produtos deles derivados, originários da planta xaxim - dicksonia sellowiana - presl - hooker 1844 pertencente à famìlia das dicksoniaceae para emprego nas seguintes áreas e setores: quìmica humana, industrial, farmacológica, biologia humana e animal, medicinal, fitomedicinal, fitoterápica, alopata, alimentìcia, nutricêutico, vitamìnico, dermatológica, cosmética e veterinária
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
JP2006522745A (ja) * 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 置換１，２，４−トリアゾールの薬学的使用
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
SE0301232D0 (sv) 2003-04-25 2003-04-25 Astrazeneca Ab Novel use
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
DE602004012578T2 (de) 2003-08-15 2008-12-11 Vertex Pharmaceuticals Inc., Cambridge Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
JP2005084612A (ja) 2003-09-11 2005-03-31 Fuji Photo Film Co Ltd ハロゲン化銀乳剤、ハロゲン化銀感光材料、および熱現像感光材料
EP1673355A1 (en) * 2003-09-22 2006-06-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
AU2004273615B2 (en) 2003-09-23 2009-01-15 Novartis Ag Combination of a VEGF receptor inhibitor with a chemotherapeutic agent
JP2007506763A (ja) 2003-09-24 2007-03-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なイミダゾール組成物
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
EP1677786A1 (en) 2003-10-18 2006-07-12 Bayer HealthCare AG 5-substituted 2-(phenylmethyl)thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases
MXPA06004657A (es) 2003-10-28 2006-06-27 Pharmacia Corp Combinaciones que comprenden un inhibidor de hsp90 y un inhibidor de fosfodiesterasa para tratar o prevenir la neoplasia.
WO2005044194A2 (en) 2003-10-28 2005-05-19 Pharmacia Corporation TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
CA2558224A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
JP2007530589A (ja) * 2004-03-26 2007-11-01 アンフォラ ディスカバリー コーポレーション 特定のトリアゾールを基礎とする化合物、組成物、およびそれらの使用
DE102004039280A1 (de) 2004-08-13 2006-02-23 Merck Patent Gmbh 1,5-Diphenyl-pyrazole
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
EP1857446B1 (en) 2005-03-09 2013-05-01 Nippon Kayaku Kabushiki Kaisha Derivatives of 3-(2,4-dihydroxyphenyl)-1,2,4-triazole useful in the treatment of cancer
JP2008137894A (ja) 2005-03-22 2008-06-19 Nippon Kayaku Co Ltd 新規なアセチレン誘導体
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
WO2007021966A1 (en) * 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
CA2618724A1 (en) * 2005-08-18 2007-02-22 Synta Pharmaceuticals Corp. Imidazole compounds that modulate hsp90 activity
JP5118039B2 (ja) * 2005-08-18 2013-01-16 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
AU2007267852A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate Hsp90 activity and methods for identifying same
US8034834B2 (en) * 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
US8063083B2 (en) * 2006-05-25 2011-11-22 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
CA2653332A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2007139967A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2034996A2 (en) * 2006-05-25 2009-03-18 Synta Pharmaceuticals Corporation Triazole compounds that modulate hsp90 activity
CA2659425C (en) * 2006-08-17 2017-06-20 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2008051416A2 (en) 2006-10-19 2008-05-02 Synta Pharmaceuticals Corp. Compounds that inhibit the activity of hsp90 for treating infections
US20100280032A1 (en) 2006-10-26 2010-11-04 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
MX2009008547A (es) 2007-02-08 2010-01-15 Synta Pharmaceuticals Corp Compuestos de triazol que son utiles en el tratamiento de trastornos proliferativos tales como cancer.
TW200904417A (en) 2007-02-20 2009-02-01 Synta Pharmaceuticals Corp Triazole compounds that modulate Hsp90 activity
WO2008112199A1 (en) 2007-03-12 2008-09-18 Synta Pharmaceuticals Corp. Method for inhibiting topoisomerase ii
ES2395114T3 (es) 2007-03-27 2013-02-08 Synta Pharmaceuticals Corporation Derivados de triazinona y de diazinona útiles como inhibidores de Hsp90
US8648104B2 (en) 2007-05-25 2014-02-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with mutations in c-Met
JP5596543B2 (ja) 2007-08-13 2014-09-24 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
US8548104B2 (en) * 2010-11-23 2013-10-01 Siano Mobile Silicon Ltd. Receiver with configurable clock frequencies

Also Published As

Publication number Publication date
WO2006055760A9 (en) 2006-09-21
AU2005306484A1 (en) 2006-05-26
TWI380983B (zh) 2013-01-01
ES2399241T3 (es) 2013-03-26
US20060167070A1 (en) 2006-07-27
NZ555158A (en) 2010-09-30
AU2005306484C1 (en) 2015-07-23
US7825148B2 (en) 2010-11-02
CA2586612A1 (en) 2006-05-26
EP2298748A3 (en) 2011-04-27
CN101072759B (zh) 2013-06-19
DK1817295T3 (da) 2013-02-18
CN101072759A (zh) 2007-11-14
CA2586612C (en) 2016-10-11
MX2007005940A (es) 2007-06-19
EP2295416A3 (en) 2011-05-04
RS52642B (en) 2013-06-28
TW200637831A (en) 2006-11-01
US9090569B2 (en) 2015-07-28
EP1817295A1 (en) 2007-08-15
PL1817295T3 (pl) 2013-04-30
PT1817295E (pt) 2013-02-18
US20110009397A1 (en) 2011-01-13
EP2295416B1 (en) 2016-01-27
EP1817295B1 (en) 2012-11-07
JP2008520702A (ja) 2008-06-19
HRP20130095T1 (hr) 2013-03-31
AU2005306484B2 (en) 2010-03-18
IL183108A (en) 2016-05-31
KR20140006070A (ko) 2014-01-15
JP4954083B2 (ja) 2012-06-13
WO2006055760A1 (en) 2006-05-26
BRPI0518315B8 (pt) 2021-05-25
US8901308B2 (en) 2014-12-02
KR20070086353A (ko) 2007-08-27
KR101374553B1 (ko) 2014-03-17
BRPI0518315B1 (pt) 2020-11-17
CN103554042B (zh) 2016-08-10
ES2594874T3 (es) 2016-12-23
EP2295416A2 (en) 2011-03-16
IL183108A0 (en) 2007-09-20
CN103554042A (zh) 2014-02-05
US20110105749A1 (en) 2011-05-05
EP2298748A2 (en) 2011-03-23
US20120330009A1 (en) 2012-12-27
ME01498B (me) 2014-04-20
HK1107700A1 (en) 2008-04-11
US8362055B2 (en) 2013-01-29
EP2298748B1 (en) 2016-07-20

Similar Documents

Publication Publication Date Title
BRPI0518315A2 (pt) compostos de tiazol que modulam a atividade da proteÍna hsp90, mÉtodos de inibiÇço, tratamento e induÇço associados e composiÇço farmacÊutica
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BRPI0622054B8 (pt) composto e composição farmacêutica
MX2010001565A (es) Compuestos triazolicos que modulan la actividad de proteina de choque termico (hsp) 90.
MX2009008547A (es) Compuestos de triazol que son utiles en el tratamiento de trastornos proliferativos tales como cancer.
TW200738234A (en) Triazole compounds that modulate HSP90 activity
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
BRPI0511350A (pt) composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
NO20092569L (no) Inhibitorer av Akt-aktivitet
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX2010014233A (es) Compuestos quimicos 251.
BR112012009215A2 (pt) "terapia combinada contra o cancer com compostos inibidores de hsp90"
WO2007139955A3 (en) Triazole compounds that modulate hsp90 activity
EA201000900A1 (ru) Ингибиторы кинезина в качестве средств для лечения рака
IN2014MN00139A (pt)
TW200628473A (en) Novel heterocycles
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
BRPI0509653A (pt) inibidores cinesina mitótica
BR112017016973A2 (pt) terapia de combinação de inibidores de hsp90 e inibidores de pd-1 para tratamento de câncer
WO2007008502A3 (en) Inhibitors of checkpoint kinases
WO2007084135A3 (en) Inhibitors of checkpoint kinases
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF